Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Seattle-Based Biotechnology Firm Dendreon Strikes Gold with CEO.
- By Luke Timmerman, The Seattle Times Knight Ridder/Tribune Business News Mar. 29--Mitchell Gold had just turned 30, had a mortgage, two young sons and a rising medical career. He had become chief resident in urology at the University of Washington, which could...
- Research articles 2004-03-29
- Dendreon To Acquire Corvas; New Company Will Have Multiple Clinical Products, Significant Oncology R&D Pipeline, Strong Cash Position and Experienced Management Team
- Business Editors/Health/Medical Writers BIOWIRE2K SEATTLE & SAN DIEGO--BUSINESS WIRE--Feb. 25, 2003 Dendreon (Nasdaq:DNDN) and Corvas (Nasdaq:CVAS), jointly announced today that they have signed a definitive merger agreement under which Dendreon will acquire Corvas in a strategic transaction that creates a combined company with a strong clinical and...
- Research articles 2003-02-25
- Cancer-Drug Report Gives Good News to Seattle-Based Biotech Firm Dendreon.
- By Luke Timmerman, The Seattle Times Knight Ridder/Tribune Business News Aug. 10--Dendreon unveiled pivotal results for its prostate-cancer treatment yesterday, and although it did not hit its goal in patients with the most aggressive tumors, it did show significant benefits for ...
- Research articles 2002-08-10
- Biotech leader pleads his sector's special case.
- Feb 21, 2002 BRW ABIX via COMTEX -- Dendreon is a member of the biotechnology industry and the company works on the development of therapeutic products. Dendreon is listed on the Nasdaq exchange in the US. The chief executive of Dendreon, Chris Henney, says...
- Research articles 2002-02-20
- Vultures Circle Dendreon Even Though Jury Is Still Out on Provenge
- Dendreon had better pull something amazing out of the hat when it gets the results of its "Impact" study on Provenge, the drug it's developing for prostate cancer -- because investors are already guessing that the results are not going to be good. Back in March, Dendreon...
- Blog posts 2008-08-15
- Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s Critics
- Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s CriticsRE: Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s CriticsThe final result has to show a 22% reduction in deaths. The interim showed a 20% reduction, closely matching previous trials. The final result of previous trials showed a 33% reduction...
- Discussion threads 2008-10-07
- Dendreon's Provenge Beats FDA Approval Standard By Just Half a Percent; Stock Plunges Before Rally
- Dendreon's IMPACT study of its cancer vaccine Provenge beat the FDA's 22 percent "reduction in risk of death" standard by just half a percent: The company said it reduced "risk of death" by 22.5 percent today. Dendreon stock plunged on the news and trading in it had to be halted,...
- Blog posts 2009-04-28
- Dendreon Still Faces Hurdles for Provenge Despite Positive Phase 3 Data
- Dendreon’s announcement that its Phase 3 prostate cancer vaccine Provenge “met its primary endpoint of improving overall survival” in the crucial IMPACT trial will likely have the prostate cancer activists dancing in the streets. But Provenge still faces significant scientific, regulatory and financial hurdles before it validates the massive expectations...
- Blog posts 2009-04-15
- Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s Critics
- It's been a just a day since Dendreon announced that the interim analysis of its Provenge anti-prostate cancer candidate showed some -- but not enough -- improvement in sufferers, and already the drug's army of web activists is heaping abuse on those who suggest that possibly, just possibly, this drug...
- Blog posts 2008-10-07
- Dendreon Gets Another Analyst Thumbs-Down
- Mike Huckman submits: I know I blogged as recently as last week that I thought there wouldn't be much reason to write about Dendreon DNDN for awhile, but I couldn't help myself when I got an email Wednesday night from Merriman Curhan Ford, which is launching coverage of DNDN...
- External links 2008-10-17
Additional Resources
- StockProfit.com New Technical Trading Alert: Dendreon Corporation (NASDAQ: DNDN).
- M2 PRESSWIRE-4 May 2007-StockProfit.com: StockProfit.com New Technical Trading Alert: Dendreon Corporation (NASDAQ: DNDN)C1994-2007 M2 COMMUNICATIONS LTD RDATE:04052007 StockProfit.com Issues a New Technical Trading Alert on Dendreon Corporation (NASDAQ: DNDN) Los Angeles, CA - Tony Golan, Chief Technical Analyst...
- Research articles 2007-05-04
- Dendreon Forms Research Alliance with Mayo Clinic
- MOUNTAIN VIEW, Calif.--BW HealthWire--Oct. 13, 1997--Dendreon Corp. formerly Activated Cell Therapy today announced a research collaboration with the Mayo Clinic of Rochester, Minn., aimed at furthering the development of Dendreon's cell therapy technology. Included in the agreement is the establishment at the Mayo Clinic of a cell...
- Research articles 1997-10-13
- Dendreon Corporation to Participate in UBS Warburg Global Life Sciences Conference
- Business Editors, Health/Medical Writers BIOWIRE2K SEATTLE--BUSINESS WIRE--Oct. 1, 2002 Dendreon Corporation (Nasdaq:DNDN) today announced that Mitchell H. Gold, chief business officer, will present at the UBS Warburg Global Life Sciences Conference at 1 p.m. Eastern time, Oct. 9 at the Plaza Hotel in New York City. ...
- Research articles 2002-10-01
- Dendreon 2007 Annual Report and How Provenge Will Propel Company
- Chris Katje submits: I have finally gotten around to writing about some of the annual reports I have sifted through in the past month. The first one I am writing about today is Dendreon DNDN, one of my Top Ten Stocks for 2009.Dendreon had a nice 2007 as far...
- External links 2009-01-27
- How Much Is Dendreon Worth?
- Dan Grundig submits: Before diving into the valuation process, here is a quick recap of recent Provenge history, and what to expect in the near future. Provenge, developed by Dendreon Corporation DNDN, is an active cellular immunotherapy (i.e. vaccine) for treatment of metastatic, androgen independent prostate cancer...
- External links 2009-04-19
- Dendreon: At Times Wall Street Resembles a Casino
- Chad Brand submits: You may have heard about Dendreon DNDN, a small money losing biotechnology company that is in the process of getting its cancer vaccine, Provenge, approved by the FDA. Full results from a crucial phase three study were released Tuesday afternoon in Chicago, but about half an...
- External links 2009-04-30
- Dendreon's Provenge Is Scientifically Intriguing but Commercially Nonsensical
- Michael Steinberg submits: I know that Dendreon’s DNDN groupies are an enthusiastic bunch. Now Wall Street has joined the party, at least until they get the fees from Dendreon’s inevitable secondary stock offering needed to fund Provenge’s launch. Dendreon doesn’t plan on filing for FDA marketing approval until sometime in...
- External links 2009-04-30
- Zacks.com Announces That Nadine Wong Highlights: Dendreon
- CHICAGO -- Nadine Wong, editor of the BioTech Stock Report newsletter, thinks Dendreon (NASDAQ:DNDN) will ultimately prevail with its prostate cancer treatment Provenge. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84 Highlights from the June 1st Featured Expert column by Nadine Wong include: Unappreciated -- Dendreon...
- Research articles 2005-06-03
- Zacks.com announces that Nadine Wong highlights: Dendreon
- CHICAGO -- Nadine Wong, editor of the BioTech Stock Report newsletter, says over the next 6 -12 months, there will be opportune times to sell Dendreon (Nasdaq:DNDN). Benefit from her insight. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84. Highlights from the September 5 Featured Expert column...
- Research articles 2006-09-08
- Dendreon and Charter Medical Announce Supply and Marketing Agreement for Stem Cell Enrichment Device
- Business Editors, Health/Medical Writers SEATTLE--BW HealthWire--Aug. 10, 2000 Dendreon Corporation (Nasdaq:DNDN) and Lydall, Inc. (NYSE:LDL) today announced the signing of a Supply and Marketing Agreement between Dendreon and Charter Medical, Ltd., a Lydall subsidiary, to distribute Dendreon's DACSRSC medical device. Under the agreement, Charter Medical has been...
- Research articles 2000-08-10
- << Previous
- page 1 of 1
- Next >>
